Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis

被引:4
作者
Lu, Lanpeng [1 ,2 ]
Chen, Chaohu [1 ,2 ]
Cheng, Hui [1 ,2 ]
Ding, Hui [1 ,2 ]
Tian, Junqiang [1 ,2 ]
Wang, Hanzhang [3 ,4 ]
Wang, Zhiping [1 ,2 ]
机构
[1] Lanzhou Univ, Hosp 2, Inst Urol, Lanzhou, Peoples R China
[2] Key Lab Gansu Prov Urol Dis, Lanzhou, Peoples R China
[3] UConn Hlth Farmington, Dept Pathol, Farmington, CT USA
[4] UConn Hlth Farmington, Lab Med, Farmington, CT USA
关键词
Bladder cancer; Neoadjuvant chemotherapy; Gemcitabine; Cisplatin; DOSE-DENSE METHOTREXATE; PHASE-III TRIAL; RADICAL CYSTECTOMY; PLUS CISPLATIN; ADJUVANT CHEMOTHERAPY; VINBLASTINE; DOXORUBICIN; SURVIVAL; EFFICACY; MULTICENTER;
D O I
10.1186/s12885-023-11572-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIn muscle-invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) combined with radical cystectomy (RC) is critical in reducing disease recurrence, with GC (gemcitabine and cisplatin) being one of the most commonly used NACs. Different GC schedules have been used, but the best neoadjuvant regimen is still unknown. The clinical outcomes of 3 and 4 cycles of neoadjuvant GC are compared in this systematic review and meta-analysis to determine which is best for patients with MIBC.MethodsWe searched PubMed, Embase, Web of Science, Cochrane Library, CBM, CNKI, WAN FANG DATA, and meeting abstracts to identify relevant studies up to March 2023. Studies that compared 3 and 4 cycles of neoadjuvant GC for MIBC were included. The primary outcomes were pCR, pDS, OS, and CSS. The secondary outcome was recurrence and SAEs.ResultsA total of 3 studies, with 1091 patients, were included in the final analysis. Patients that received 4 cycles of GC had a higher pCR (OR = 0.66; 95% CI, 0.50-0.87; p = 0.003) and pDS (OR = 0.63; 95% CI, 0.48-0.84; p = 0.002) than those who received 3 cycles. Regarding recurrence rate (OR = 1.23; 95% CI, 0.91-1.65; p = 0.18), there were no appreciable differences between the 3 and 4 cycles of GC. Survival parameters such as OS (HR, 1.35; 95% CI, 0.86-2.12; p = 0.19) and CSS (HR, 1.06; 95% CI, 0.82-1.38; p = 0.20) were similar. Only one trial reported on the outcomes of SAEs. And there were no statistically significant differences in thrombocytopenia, infection rate, neutropenic fever, anemia, or decreased renal function between patients. The neutropenia of patients was statistically different (OR = 0.72; 95% CI, 0.52-0.99; p = 0.04).ConclusionThe 4-cycle GC regimen was superior to the 3-cycle regimen in only the pCR and pDS results. Survival and recurrence rates were similar between the two regimens. In both treatment regimes, the toxicity profile was manageable. However, due to the inherent drawbacks of retrospective research, this should be regarded with caution.
引用
收藏
页数:12
相关论文
共 60 条
[1]   Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer [J].
Aydin, Ahmet Murat ;
Cheriyan, Salim K. ;
Reich, Richard ;
Hajiran, Ali ;
Peyton, Charles C. ;
Zemp, Logan ;
Yu, Alice ;
Li, Roger ;
Poch, Michael A. ;
Spiess, Philippe E. ;
Jain, Rohit ;
Zhang, Jingsong ;
Sexton, Wade J. ;
Gilbert, Scott M. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (10) :453.e19-453.e26
[2]   Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [J].
Bahadoer, Renu R. ;
Dijkstra, Esmee A. ;
van Etten, Boudewijn ;
Marijnen, Corrie A. M. ;
Putter, Hein ;
Kranenbarg, Elma Meershoek-Klein ;
Roodvoets, Annet G. H. ;
Nagtegaal, Iris D. ;
Beets-Tan, Regina G. H. ;
Blomqvist, Lennart K. ;
Fokstuen, Tone ;
ten Tije, Albert J. ;
Capdevila, Jaume ;
Hendriks, Mathijs P. ;
Edhemovic, Ibrahim ;
Cervantes, Andres ;
Nilsson, Per J. ;
Glimelius, Bengt ;
van de Velde, Cornelis J. H. ;
Hospers, Geke A. P. .
LANCET ONCOLOGY, 2021, 22 (01) :29-42
[3]  
Blanco-Martinez E, 2021, J UROLOGY, V206, pE764
[4]   Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience [J].
Boeri, Luca ;
Soligo, Matteo ;
Frank, Igor ;
Boorjian, Stephen A. ;
Thompson, R. Houston ;
Tollefson, Matthew ;
Tarrel, Robert ;
Quevedo, Fernando J. ;
Cheville, John C. ;
Karnes, R. Jeffrey .
WORLD JOURNAL OF UROLOGY, 2019, 37 (11) :2409-2418
[5]   Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline [J].
Chang, Sam S. ;
Bochner, Bernard H. ;
Chou, Roger ;
Dreicer, Robert ;
Kamat, Ashish M. ;
Lerner, Seth P. ;
Lotan, Yair ;
Meeks, Joshua J. ;
Michalski, Jeff M. ;
Morgan, Todd M. ;
Quale, Diane Z. ;
Rosenberg, Jonathan E. ;
Zietman, Anthony L. ;
Holzbeierlein, Jeffrey M. .
JOURNAL OF UROLOGY, 2017, 198 (03) :552-559
[6]   Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscleinvasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy [J].
Chen, Jinbo ;
Wang, Long ;
Tang, Yunhua ;
Gong, Guanghui ;
Liu, Longfei ;
Chen, Minfeng ;
Chen, Zhi ;
Cui, Yu ;
Li, Chao ;
Cheng, Xu ;
Qi, Lin ;
Zu, Xiongbing .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
[7]  
Chung DY, 2021, Cancers (Basel), P13
[8]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[9]   Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer [J].
D'Andrea, David ;
Black, Peter C. ;
Zargar, Homayoun ;
Dinney, Colin P. ;
Soria, Francesco ;
Cookson, Michael S. ;
Montgomery, Jeffrey S. ;
Kassouf, Wassim ;
Dall'Era, Marc A. ;
Sridhar, Srikala S. ;
McGrath, John S. ;
Wright, Jonathan L. ;
Thorpe, Andrew C. ;
Holzbeierlein, Jeff M. ;
Carrion, Diego M. ;
Di Trapani, Ettore ;
Bivalacqua, Trinity J. ;
North, Scott ;
Barocas, Daniel A. ;
Lotan, Yair ;
Grivas, Petros ;
Stephenson, Andrew J. ;
van Rhijn, Bas W. ;
Daneshmand, Siamak ;
Spiess, Philippe E. ;
Shariat, Shahrokh F. ;
Zargar-Shoshtar, Kamran ;
Mertens, Laura S. ;
Fairey, Adrian S. ;
Mir, Maria C. ;
Krabbe, Laura-Maria ;
Jacobsen, Niels-Erik ;
Vasdev, Nikhil ;
Yu, Evan Y. ;
Xylinas, Evanguelos ;
Pradere, Benjamin ;
Pichler, Renate ;
Campain, Nicholas J. ;
Seah, Jo-An ;
Ercole, Cesar E. ;
Horenblas, Simon ;
Aning, Jonathan ;
Morgan, Todd M. ;
Shah, Jay B. ;
Moschini, Marco .
JOURNAL OF UROLOGY, 2022, 207 (01) :70-76
[10]  
de Vries Gerda, 2020, Cancer Treat Rev, V88, P102054, DOI 10.1016/j.ctrv.2020.102054